December 2022 Alzheimer’s News

As a follow-up from our October 2022 Alzheimer’s News, this past week researchers gathered in San Francisco. Data from the Phase 3 global clinical trial of lecanemab confirmed this treatment changes the course of the disease in a meaningful way for people in the earliest stages of Alzheimer’s Disease. The Alzheimer’s Association has called for the Food and Drug administration’s (FDA) accelerated approval of lecanemab and for the Centers for Medicare and Medicaid Services (CMS) to revise its coverage policy with the utmost urgency.

You can learn more by going to www.alz.org/help-support/resources or the Alzheimer’s Helpline which is accessible 24/7 via 800-272-3900 and staffed by master’s level clinicians to assist with crisis situations, decision making, and disease information. You can find virtual dementia caregiver resources online at alz.org/covid19help. Tools and support are also available in Spanish.
Want to learn more about the Alzheimer’s Association and what they do here in St. Louis? Visit alz.org and/or contact PUCC’s Faith Outreach Ambassador with the Alzheimer’s Association, Joyce Ruiz at joyceruiz7@gmail.com

Post Date: December 9, 2022